This content is from: Home

Analysis: Why biotech industry must adapt patent strategies following Myriad

The Supreme Court ruled in Myriad earlier this month that isolated genomic DNA is ineligible for patent protection. Alli Pyrah reports on strategies the biotech industry might now take to protect genetic inventions

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial